MicroRNA-423 may regulate diabetic vasculopathy

To test the hypothesis that microRNAs may play a role in diabetic retinopathy, we measured the levels of different markers [microRNAs, vascular endothelial growth factor (VEGF), nitric oxide (NO), and total antioxidant capacity (TAO)] in patients with type 2 diabetes mellitus (T2DM) and microvascula...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental medicine 2019-11, Vol.19 (4), p.469-477
Hauptverfasser: Blum, Arnon, Meerson, Ari, Rohana, Hanan, Jabaly, Hanin, Nahul, Nahul, Celesh, Dorina, Romanenko, Olga, Tamir, Snait
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 477
container_issue 4
container_start_page 469
container_title Clinical and experimental medicine
container_volume 19
creator Blum, Arnon
Meerson, Ari
Rohana, Hanan
Jabaly, Hanin
Nahul, Nahul
Celesh, Dorina
Romanenko, Olga
Tamir, Snait
description To test the hypothesis that microRNAs may play a role in diabetic retinopathy, we measured the levels of different markers [microRNAs, vascular endothelial growth factor (VEGF), nitric oxide (NO), and total antioxidant capacity (TAO)] in patients with type 2 diabetes mellitus (T2DM) and microvascular complications. Sixty-nine patients were recruited: 22 healthy subjects, ten T2DM patients without retinopathy, 22 with nonproliferative diabetic retinopathy, and 15 with proliferative diabetic retinopathy (PDR). Serum levels of NO, VEGF, TAO and 16 candidate microRNAs were measured. Additionally, the mRNA levels of endothelial nitric oxide synthase (eNOS), induced NOS (iNOS), C reactive protein (CRP), VEGF, tumor necrosis factor α (TNFα), PON2, p22, and SOD2 were measured in human vascular endothelial cells cultured in the presence of pooled sera from the subject groups. Plasma miR-423 levels showed a significant ~ twofold decrease in patients with PDR compared to controls. P lasma NO levels were significantly higher in retinopathy, VEGF levels were significantly lower, and TAO was significantly decreased. eNOS mRNA levels were lower in the cells of T2DM patients without retinopathy, but higher in PDR. PON2, p22, and SOD2 mRNA levels were all significantly lower in PDR. CRP, TNFα, iNOS, and VEGF mRNA levels showed no significant association with disease status. Lowered miR-423 levels in diabetic patients showed a correlation with VEGF and an inverse correlation between NO and eNOS expression. Our findings suggest a cross talk between miR-423 and VEGF signaling, affecting eNOS function. miR-423 may be involved in the regulation of diabetic vascular retinal proliferation.
doi_str_mv 10.1007/s10238-019-00573-8
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2275952310</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2275952310</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-7b6fdb208fb683244868f595f83ed4b5525963abd142eb8e47c447dd740fa9423</originalsourceid><addsrcrecordid>eNp9kM1LwzAchoMobk7_AQ9S8OIl7pevJj2O4RdMBdFzSNp0drTrTFph_73RTgUPkkMCeX5v3jwInRK4JAByGghQpjCQDAMIybDaQ2MiMoIzQdX-7qxUBiN0FMIKgAjF4BCNGOGUCpKO0fS-yn379DDDnLKkMdvEu2Vfm84lRWWs66o8eTch7-t2Y7rX7TE6KE0d3Mlun6CX66vn-S1ePN7czWcLnDMpOixtWhaWgiptqhjlXKWqFJkoFXMFt0JQkaXM2CIWcVY5LnPOZVFIDqXJYpUJuhhyN759613odFOF3NW1Wbu2D5pSGeMoIxDR8z_oqu39OrbTlEEqGIkrUnSg4ndD8K7UG181xm81Af2pUw86ddSpv3RqFYfOdtG9bVzxM_LtLwJsAEK8Wi-d_337n9gPMRJ81A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2306531313</pqid></control><display><type>article</type><title>MicroRNA-423 may regulate diabetic vasculopathy</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Blum, Arnon ; Meerson, Ari ; Rohana, Hanan ; Jabaly, Hanin ; Nahul, Nahul ; Celesh, Dorina ; Romanenko, Olga ; Tamir, Snait</creator><creatorcontrib>Blum, Arnon ; Meerson, Ari ; Rohana, Hanan ; Jabaly, Hanin ; Nahul, Nahul ; Celesh, Dorina ; Romanenko, Olga ; Tamir, Snait</creatorcontrib><description>To test the hypothesis that microRNAs may play a role in diabetic retinopathy, we measured the levels of different markers [microRNAs, vascular endothelial growth factor (VEGF), nitric oxide (NO), and total antioxidant capacity (TAO)] in patients with type 2 diabetes mellitus (T2DM) and microvascular complications. Sixty-nine patients were recruited: 22 healthy subjects, ten T2DM patients without retinopathy, 22 with nonproliferative diabetic retinopathy, and 15 with proliferative diabetic retinopathy (PDR). Serum levels of NO, VEGF, TAO and 16 candidate microRNAs were measured. Additionally, the mRNA levels of endothelial nitric oxide synthase (eNOS), induced NOS (iNOS), C reactive protein (CRP), VEGF, tumor necrosis factor α (TNFα), PON2, p22, and SOD2 were measured in human vascular endothelial cells cultured in the presence of pooled sera from the subject groups. Plasma miR-423 levels showed a significant ~ twofold decrease in patients with PDR compared to controls. P lasma NO levels were significantly higher in retinopathy, VEGF levels were significantly lower, and TAO was significantly decreased. eNOS mRNA levels were lower in the cells of T2DM patients without retinopathy, but higher in PDR. PON2, p22, and SOD2 mRNA levels were all significantly lower in PDR. CRP, TNFα, iNOS, and VEGF mRNA levels showed no significant association with disease status. Lowered miR-423 levels in diabetic patients showed a correlation with VEGF and an inverse correlation between NO and eNOS expression. Our findings suggest a cross talk between miR-423 and VEGF signaling, affecting eNOS function. miR-423 may be involved in the regulation of diabetic vascular retinal proliferation.</description><identifier>ISSN: 1591-8890</identifier><identifier>EISSN: 1591-9528</identifier><identifier>DOI: 10.1007/s10238-019-00573-8</identifier><identifier>PMID: 31422516</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Adult ; Aged ; Antioxidants ; C-reactive protein ; Case-Control Studies ; Diabetes ; Diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetic retinopathy ; Diabetic Retinopathy - blood ; Diabetic Retinopathy - genetics ; Down-Regulation ; Endothelial cells ; Female ; Genetic Predisposition to Disease ; Hematology ; Human Umbilical Vein Endothelial Cells ; Humans ; Internal Medicine ; Male ; Medicine ; Medicine &amp; Public Health ; MicroRNAs ; MicroRNAs - blood ; Microvasculature ; Middle Aged ; miRNA ; mRNA ; Nitric oxide ; Nitric Oxide - blood ; Nitric Oxide Synthase Type III - blood ; Nitric Oxide Synthase Type III - genetics ; Nitric-oxide synthase ; Oncology ; Original Article ; Retina ; Retinopathy ; Serum levels ; Superoxide dismutase ; Tumor necrosis factor-α ; Vascular diseases ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - blood</subject><ispartof>Clinical and experimental medicine, 2019-11, Vol.19 (4), p.469-477</ispartof><rights>Springer Nature Switzerland AG 2019</rights><rights>Copyright Springer Nature B.V. 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-7b6fdb208fb683244868f595f83ed4b5525963abd142eb8e47c447dd740fa9423</citedby><cites>FETCH-LOGICAL-c375t-7b6fdb208fb683244868f595f83ed4b5525963abd142eb8e47c447dd740fa9423</cites><orcidid>0000-0003-3863-4036</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10238-019-00573-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10238-019-00573-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31422516$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Blum, Arnon</creatorcontrib><creatorcontrib>Meerson, Ari</creatorcontrib><creatorcontrib>Rohana, Hanan</creatorcontrib><creatorcontrib>Jabaly, Hanin</creatorcontrib><creatorcontrib>Nahul, Nahul</creatorcontrib><creatorcontrib>Celesh, Dorina</creatorcontrib><creatorcontrib>Romanenko, Olga</creatorcontrib><creatorcontrib>Tamir, Snait</creatorcontrib><title>MicroRNA-423 may regulate diabetic vasculopathy</title><title>Clinical and experimental medicine</title><addtitle>Clin Exp Med</addtitle><addtitle>Clin Exp Med</addtitle><description>To test the hypothesis that microRNAs may play a role in diabetic retinopathy, we measured the levels of different markers [microRNAs, vascular endothelial growth factor (VEGF), nitric oxide (NO), and total antioxidant capacity (TAO)] in patients with type 2 diabetes mellitus (T2DM) and microvascular complications. Sixty-nine patients were recruited: 22 healthy subjects, ten T2DM patients without retinopathy, 22 with nonproliferative diabetic retinopathy, and 15 with proliferative diabetic retinopathy (PDR). Serum levels of NO, VEGF, TAO and 16 candidate microRNAs were measured. Additionally, the mRNA levels of endothelial nitric oxide synthase (eNOS), induced NOS (iNOS), C reactive protein (CRP), VEGF, tumor necrosis factor α (TNFα), PON2, p22, and SOD2 were measured in human vascular endothelial cells cultured in the presence of pooled sera from the subject groups. Plasma miR-423 levels showed a significant ~ twofold decrease in patients with PDR compared to controls. P lasma NO levels were significantly higher in retinopathy, VEGF levels were significantly lower, and TAO was significantly decreased. eNOS mRNA levels were lower in the cells of T2DM patients without retinopathy, but higher in PDR. PON2, p22, and SOD2 mRNA levels were all significantly lower in PDR. CRP, TNFα, iNOS, and VEGF mRNA levels showed no significant association with disease status. Lowered miR-423 levels in diabetic patients showed a correlation with VEGF and an inverse correlation between NO and eNOS expression. Our findings suggest a cross talk between miR-423 and VEGF signaling, affecting eNOS function. miR-423 may be involved in the regulation of diabetic vascular retinal proliferation.</description><subject>Adult</subject><subject>Aged</subject><subject>Antioxidants</subject><subject>C-reactive protein</subject><subject>Case-Control Studies</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetic retinopathy</subject><subject>Diabetic Retinopathy - blood</subject><subject>Diabetic Retinopathy - genetics</subject><subject>Down-Regulation</subject><subject>Endothelial cells</subject><subject>Female</subject><subject>Genetic Predisposition to Disease</subject><subject>Hematology</subject><subject>Human Umbilical Vein Endothelial Cells</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>MicroRNAs</subject><subject>MicroRNAs - blood</subject><subject>Microvasculature</subject><subject>Middle Aged</subject><subject>miRNA</subject><subject>mRNA</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - blood</subject><subject>Nitric Oxide Synthase Type III - blood</subject><subject>Nitric Oxide Synthase Type III - genetics</subject><subject>Nitric-oxide synthase</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Retina</subject><subject>Retinopathy</subject><subject>Serum levels</subject><subject>Superoxide dismutase</subject><subject>Tumor necrosis factor-α</subject><subject>Vascular diseases</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A - blood</subject><issn>1591-8890</issn><issn>1591-9528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1LwzAchoMobk7_AQ9S8OIl7pevJj2O4RdMBdFzSNp0drTrTFph_73RTgUPkkMCeX5v3jwInRK4JAByGghQpjCQDAMIybDaQ2MiMoIzQdX-7qxUBiN0FMIKgAjF4BCNGOGUCpKO0fS-yn379DDDnLKkMdvEu2Vfm84lRWWs66o8eTch7-t2Y7rX7TE6KE0d3Mlun6CX66vn-S1ePN7czWcLnDMpOixtWhaWgiptqhjlXKWqFJkoFXMFt0JQkaXM2CIWcVY5LnPOZVFIDqXJYpUJuhhyN759613odFOF3NW1Wbu2D5pSGeMoIxDR8z_oqu39OrbTlEEqGIkrUnSg4ndD8K7UG181xm81Af2pUw86ddSpv3RqFYfOdtG9bVzxM_LtLwJsAEK8Wi-d_337n9gPMRJ81A</recordid><startdate>20191101</startdate><enddate>20191101</enddate><creator>Blum, Arnon</creator><creator>Meerson, Ari</creator><creator>Rohana, Hanan</creator><creator>Jabaly, Hanin</creator><creator>Nahul, Nahul</creator><creator>Celesh, Dorina</creator><creator>Romanenko, Olga</creator><creator>Tamir, Snait</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3863-4036</orcidid></search><sort><creationdate>20191101</creationdate><title>MicroRNA-423 may regulate diabetic vasculopathy</title><author>Blum, Arnon ; Meerson, Ari ; Rohana, Hanan ; Jabaly, Hanin ; Nahul, Nahul ; Celesh, Dorina ; Romanenko, Olga ; Tamir, Snait</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-7b6fdb208fb683244868f595f83ed4b5525963abd142eb8e47c447dd740fa9423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antioxidants</topic><topic>C-reactive protein</topic><topic>Case-Control Studies</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetic retinopathy</topic><topic>Diabetic Retinopathy - blood</topic><topic>Diabetic Retinopathy - genetics</topic><topic>Down-Regulation</topic><topic>Endothelial cells</topic><topic>Female</topic><topic>Genetic Predisposition to Disease</topic><topic>Hematology</topic><topic>Human Umbilical Vein Endothelial Cells</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>MicroRNAs</topic><topic>MicroRNAs - blood</topic><topic>Microvasculature</topic><topic>Middle Aged</topic><topic>miRNA</topic><topic>mRNA</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - blood</topic><topic>Nitric Oxide Synthase Type III - blood</topic><topic>Nitric Oxide Synthase Type III - genetics</topic><topic>Nitric-oxide synthase</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Retina</topic><topic>Retinopathy</topic><topic>Serum levels</topic><topic>Superoxide dismutase</topic><topic>Tumor necrosis factor-α</topic><topic>Vascular diseases</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Blum, Arnon</creatorcontrib><creatorcontrib>Meerson, Ari</creatorcontrib><creatorcontrib>Rohana, Hanan</creatorcontrib><creatorcontrib>Jabaly, Hanin</creatorcontrib><creatorcontrib>Nahul, Nahul</creatorcontrib><creatorcontrib>Celesh, Dorina</creatorcontrib><creatorcontrib>Romanenko, Olga</creatorcontrib><creatorcontrib>Tamir, Snait</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Blum, Arnon</au><au>Meerson, Ari</au><au>Rohana, Hanan</au><au>Jabaly, Hanin</au><au>Nahul, Nahul</au><au>Celesh, Dorina</au><au>Romanenko, Olga</au><au>Tamir, Snait</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MicroRNA-423 may regulate diabetic vasculopathy</atitle><jtitle>Clinical and experimental medicine</jtitle><stitle>Clin Exp Med</stitle><addtitle>Clin Exp Med</addtitle><date>2019-11-01</date><risdate>2019</risdate><volume>19</volume><issue>4</issue><spage>469</spage><epage>477</epage><pages>469-477</pages><issn>1591-8890</issn><eissn>1591-9528</eissn><abstract>To test the hypothesis that microRNAs may play a role in diabetic retinopathy, we measured the levels of different markers [microRNAs, vascular endothelial growth factor (VEGF), nitric oxide (NO), and total antioxidant capacity (TAO)] in patients with type 2 diabetes mellitus (T2DM) and microvascular complications. Sixty-nine patients were recruited: 22 healthy subjects, ten T2DM patients without retinopathy, 22 with nonproliferative diabetic retinopathy, and 15 with proliferative diabetic retinopathy (PDR). Serum levels of NO, VEGF, TAO and 16 candidate microRNAs were measured. Additionally, the mRNA levels of endothelial nitric oxide synthase (eNOS), induced NOS (iNOS), C reactive protein (CRP), VEGF, tumor necrosis factor α (TNFα), PON2, p22, and SOD2 were measured in human vascular endothelial cells cultured in the presence of pooled sera from the subject groups. Plasma miR-423 levels showed a significant ~ twofold decrease in patients with PDR compared to controls. P lasma NO levels were significantly higher in retinopathy, VEGF levels were significantly lower, and TAO was significantly decreased. eNOS mRNA levels were lower in the cells of T2DM patients without retinopathy, but higher in PDR. PON2, p22, and SOD2 mRNA levels were all significantly lower in PDR. CRP, TNFα, iNOS, and VEGF mRNA levels showed no significant association with disease status. Lowered miR-423 levels in diabetic patients showed a correlation with VEGF and an inverse correlation between NO and eNOS expression. Our findings suggest a cross talk between miR-423 and VEGF signaling, affecting eNOS function. miR-423 may be involved in the regulation of diabetic vascular retinal proliferation.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>31422516</pmid><doi>10.1007/s10238-019-00573-8</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-3863-4036</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1591-8890
ispartof Clinical and experimental medicine, 2019-11, Vol.19 (4), p.469-477
issn 1591-8890
1591-9528
language eng
recordid cdi_proquest_miscellaneous_2275952310
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Adult
Aged
Antioxidants
C-reactive protein
Case-Control Studies
Diabetes
Diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - complications
Diabetic retinopathy
Diabetic Retinopathy - blood
Diabetic Retinopathy - genetics
Down-Regulation
Endothelial cells
Female
Genetic Predisposition to Disease
Hematology
Human Umbilical Vein Endothelial Cells
Humans
Internal Medicine
Male
Medicine
Medicine & Public Health
MicroRNAs
MicroRNAs - blood
Microvasculature
Middle Aged
miRNA
mRNA
Nitric oxide
Nitric Oxide - blood
Nitric Oxide Synthase Type III - blood
Nitric Oxide Synthase Type III - genetics
Nitric-oxide synthase
Oncology
Original Article
Retina
Retinopathy
Serum levels
Superoxide dismutase
Tumor necrosis factor-α
Vascular diseases
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - blood
title MicroRNA-423 may regulate diabetic vasculopathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T13%3A24%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MicroRNA-423%20may%20regulate%20diabetic%20vasculopathy&rft.jtitle=Clinical%20and%20experimental%20medicine&rft.au=Blum,%20Arnon&rft.date=2019-11-01&rft.volume=19&rft.issue=4&rft.spage=469&rft.epage=477&rft.pages=469-477&rft.issn=1591-8890&rft.eissn=1591-9528&rft_id=info:doi/10.1007/s10238-019-00573-8&rft_dat=%3Cproquest_cross%3E2275952310%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2306531313&rft_id=info:pmid/31422516&rfr_iscdi=true